Related Experiment Video
Updated: Jun 16, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume
Søren M Bentzen1, Matthew Parliament, Joseph O Deasy
1Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA. bentzen@humonc.wisc.edu
Abstract:
Biomarkers are of interest for predicting or monitoring normal tissue toxicity of radiation therapy. Advances in molecular radiobiology provide novel leads in the search for normal tissue biomarkers with sufficient sensitivity and specificity to become clinically useful. This article reviews examples of studies of biomarkers as predictive markers, as response markers, or as surrogate endpoints for radiation side effects. Single nucleotide polymorphisms are briefly discussed in the context of candidate gene and genomewide association studies. The importance of adjusting for radiation dose distribution in normal tissue biomarker studies is underlined. Finally, research priorities in this field are identified and discussed.
